Core Insights - A large number of medical companies, including Aikobio, are applying for listings on the Hong Kong Stock Exchange, indicating a trend in the healthcare sector [1] - Aikobio has previously attempted to list on the Hong Kong Stock Exchange and has shifted its focus to the A-share market, but later withdrew its application due to strategic considerations [2][3] - The company has a dual-track drug development strategy, combining both in-house research and external collaborations [8] Company Overview - Aikobio was founded in August 2013 and became a joint-stock company in March 2021, headquartered in Shanghai [5] - The company has received multiple rounds of investment from notable investors such as Hillhouse Capital and Qiming Venture Partners [5] - As of June 2025, the founder, Dr. Wu Zheng, controls 25.17% of the company and has a strong background in pharmaceutical research [6] Product Pipeline - Aikobio has developed six candidate drugs, including AK0529, which targets respiratory syncytial virus (RSV) and is in the NDA stage [10] - The company’s core product, AK0529, is the first RSV-specific antiviral drug to show positive results in pivotal Phase III trials [18] - Another key product, AK3280, is in Phase II and targets idiopathic pulmonary fibrosis (IPF), with a significant market potential projected to grow from $6.9 billion in 2024 to $22.2 billion by 2035 [23] Financial Performance - Aikobio has not yet commercialized any products and reported cumulative losses of 570 million RMB over two and a half years [28] - The company’s revenue primarily comes from a collaboration on a hepatitis B virus candidate drug, but this project has been paused [28] - As of December 2025, the company had approximately 96.73 million RMB in cash and cash equivalents, which is expected to sustain its operations for about 16 months at the current burn rate [30]
爱科百发三闯IPO，深耕儿科呼吸领域，核心药物市场空间存疑
Ge Long Hui·2025-09-30 08:55